Skip to main content

Table 2 Cost parameters input in the model

From: Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance

Parameters

Value (range)

Resource

Cabazitaxel (60 mg)

13,170.31 (10,536.248–15,804.384)

RED BOOK

Abiraterone (250 mg)

95.26 (76.208–114.312)

RED BOOK

Enzalutamide (40 mg)

115.486 (92.389–138.583)

RED BOOK

Prednisone (10 mg)

0.53 (0.424–0.636)

RED BOOK

Prednisone (5 mg)

0.39 (0.312–0.468)

RED BOOK

Administration per unit CPT:96365

74.16 (59.328–88.992)

CMS

Musculoskeletal pain or discomfort per event

364.8 (291.84–437.76)

[26], 2015

Renal disorder per event

5966.67 (4773.336–7160.004)

[27], 2015

Anemia per event

1881 (1826–1910)

[27], 2015

Leukopenia per event

3066 (2758–3384)

[27], 2015

Neutropenia per event

3066 (2758–3384)

[27], 2015

Laboratory tests per event

76 (68–84)

[27], 2015

Chest/Abdomen/Pelvis CT per event

828 (598–1083)

[27], 2015

PSA per event

25 (20–30)

[28], 2015

Bone scanning per event

253.46 (202.768–304.152)

[28], 2015

Cost of supportive care per cycle

1213 (987–1438)

[29], 2018

Routine follow-up of patients per unit

422 (348.1–495.8)

[29], 2018

  1. CT Computed Tomography, PSA prostate specific antigen